Regional lymphatic immunity in melanoma

Melanoma Research

Volumn 22, Issue 1, 2012, Pages 9-18

  Grotz, Travis E ^a   Mansfield, Aaron S ^b,c   Jakub, James W ^a   Markovic, Svetomir N ^b,c  

^a Division of Surgery   (United States)

^b Division of Hematology   (United States)

^c MAYO CLINIC   (United States)

Author keywords

immunotherapy; lymph nodes; regulatory T cells; sentinel lymph node; Th1 Th2 balance; tumor immune evasion

Indexed keywords

CANCER GROWTH; HUMAN; IMMUNITY; LYMPH NODE; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPHANGIOGENESIS; MACROPHAGE; MELANOMA; PRIORITY JOURNAL; REVIEW; TH2 CELL; TUMOR IMMUNITY;

HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MELANOMA; SKIN NEOPLASMS;

EID: 84855790423     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32834e1f33     Document Type: Review

References (99)

1. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355:1307-1317. (Pubitemid 44465459)
2. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19:3622-3634. (Pubitemid 32786275)
3. White RR, Stanley WE, Johnson JL, Tyler DS, Seigler HF. Long-term survival in 2505 patients with melanoma with regional lymph node metastasis. Ann Surg 2002; 235:879-887. (Pubitemid 34547308)
4. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and meta-analysis. J Natl Cancer Inst 2010; 102:493-501.
5. Torisu-Itakura H, Lee JH, Scheri RP, Huynh Y, Ye X, Essner R, Morton DL. Molecular characterization of inflammatory genes in sentinel and nonsentinel nodes in melanoma. Clin Cancer Res 2007; 13:3125-3132. (Pubitemid 46944893)
6. Cochran AJ, Huang RR, Lee J, Itakura E, Leong SP, Essner R. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 2006; 6:659-670. (Pubitemid 44298215)
7. Negin B, Panka D, Wang W, Siddiqui M, Tawa N, Mullen J, et al. Effect of melanoma on immune function in the regional lymph node basin. Clin Cancer Res 2008; 14:654-659. (Pubitemid 351231144)
8. Mansfield AS, Holtan SG, Grotz TE, Allred JB, Jakub JW, Erickson LA, Markovic SN. Regional immunity in melanoma: Immunosuppressive changes precede nodal metastasis. Mod Pathol 2011; 4:487-494.
9. Willis RA. The spread of tumours in the human body. London: Butterworths; 1973.
10. Stephenson KR, Perry-Lalley D, Griffith KD, Shu S, Chang AE. Development of antitumor reactivity in regional draining lymph nodes from tumorimmunized and tumor-bearing murine hosts. Surgery 1989; 105:523-528. (Pubitemid 19105062)
11. Fisher B, Fisher ER. Studies concerning the regional lymph node in cancer. I. Initiation of immunity. Cancer 1971; 27:1001-1004.
12. Fisher B, Saffer EA, Fisher ER. Studies concerning the regional lymph node in cancer. 3. Response of regional lymph node cells from breast and colon cancer patients to PHA stimulation. Cancer 1972; 30:1202-1215.
13. Wen DR, Hoon DS, Chang C, Cochran AJ. Variations in lymphokine generation by individual lymph nodes draining human malignant tumors. Cancer Immunol Immunother 1989; 30:277-282. (Pubitemid 20002341)
14. Hoon DS, Bowker RJ, Cochran AJ. Suppressor cell activity in melanomadraining lymph nodes. Cancer Res 1987; 47:1529-1533. (Pubitemid 17044477)
15. Farzad Z, McBride WH, Ogbechi H, Asnong-Holthoff C, Morton DL, Cochran AJ. Lymphocytes from lymph nodes at different distances from human melanoma vary in their capacity to inhibit/enhance tumor cell growth in vitro. Melanoma Res 1997; 7 (Suppl 2):S59-S65. (Pubitemid 27501627)
16. Hu CE, Gan J, Zhang RD, Cheng YR, Huang GJ. Up-regulated myeloidderived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function. Scand J. Gastroenterol. 2011; 46:156-164.
17. Zhao F, Obermann S, von Wasielewski R, Haile L, Manns MP, Korangy F, Greten TF. Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma. Immunology 2009; 128:141-149.
18. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, et al. Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer. J Immunol 2001; 166: 678-689. (Pubitemid 32038493)
19. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin- cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58:49-59.
20. Pan PY,Wang GX, Yin B, Ozao J, Ku T, Divino CM, Chen SH. Reversion of immune tolerance in advanced malignancy: Modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 2008; 111:219-228.
21. Bronte V, Chappell DB, Apolloni E, Cabrelle A,Wang M, Hwu P, Restifo NP. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigenpresenting cell maturation. J Immunol 1999; 162:5728-5737. (Pubitemid 29314923)
22. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004; 64:6337-6343. (Pubitemid 39129439)
23. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, Carbone DP. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92:4150-4166. (Pubitemid 28544331)
24. Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 2006; 176:284-290. (Pubitemid 43023273)
25. Song X, Krelin Y, Dvorkin T, Bjorkdahl O, Segal S, Dinarello CA, et al. CD11b +/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J Immunol 2005; 175:8200-8208. (Pubitemid 41798384)
26. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 2005; 174:636-645. (Pubitemid 40094255)
27. Melani C, Chiodoni C, Forni G, Colombo MP. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003; 102:2138-2145. (Pubitemid 37122391)
28. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al. Altered recognition of antigen is a mechanism of CD8 + T cell tolerance in cancer. Nat Med 2007; 13:828-835. (Pubitemid 47038194)
29. Bingisser RM, Tilbrook PA, Holt PG, Kees UR. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol 1998; 160:5729-5734. (Pubitemid 28298028)
30. Rivoltini L, Carrabba M, Huber V, Castelli C, Novellino L, Dalerba P, et al. Immunity to cancer: Attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 2002; 188:97-113. (Pubitemid 35398868)
31. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 2010; 70:68-77.
32. Rodriguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: Mechanisms and therapeutic perspectives. Immunol Rev 2008; 222:180-191. (Pubitemid 351430370)
33. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005; 5:641-654. (Pubitemid 41113195)
34. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004; 172: 989-999. (Pubitemid 38113758)
35. Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4 + and CD8 + T cells. J Immunol 2009; 183:937-944.
36. Lee JH, Chen Y, Chan JL, Qian YW, Goydos JS. Molecular analysis of melanoma-induced sentinel lymph node immune dysfunction. Cancer Immunol Immunother 2011; 60:685-692.
37. Steinbrink K, Graulich E, Kubsch S, Knop J, Enk AH. CD4( +) and CD8( + ) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 2002; 99: 2468-2476. (Pubitemid 34525434)
38. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Crosstalk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007; 179:977-983.
39. 4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004; 173:1444-1453. (Pubitemid 38924326)
40. Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 2006; 16:115-123. (Pubitemid 43172060)
41. Eikawa S, Ohue Y, Kitaoka K, Aji T, Uenaka A, Oka M, Nakayama E. Enrichment of Foxp3 + CD4 regulatory T cells in migrated T cells to IL-6- and IL-8-expressing tumors through predominant induction of CXCR1 by IL-6. J Immunol 2010; 185:6734-6740.
42. Brody JR, Costantino CL, Berger AC, Sato T, Lisanti MP, Yeo CJ, et al. Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle 2009; 8:1930-1934.
43. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, et al. Gr-1 + CD115 + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66:1123-1131. (Pubitemid 43165981)
44. Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res 2006; 12:6808-6816. (Pubitemid 44876851)
45. Ladanyi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A, et al. Density of DC-LAMP( +) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 2007; 56:1459-1469. (Pubitemid 47024707)
46. Simon AK, Jones E, Richards H, Wright K, Betts G, Godkin A, et al. Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity. Eur J Immunol 2007; 37:758-767. (Pubitemid 46916942)
47. Miracco C, Mourmouras V, Biagioli M, Rubegni P, Mannucci S, Monciatti I,et al. Utility of tumour-infiltrating CD25 +FOXP3 + regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma. Oncol Rep 2007; 18:1115-1122.
48. Knol AC, Nguyen JM, Quereux G, Brocard A, Khammari A, Dreno B. Prognostic value of tumor-infiltrating Foxp3 + T-cell subpopulations in metastatic melanoma. Exp Dermatol 2011; 20:430-434.
49. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26:5233-5239.
50. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23:2346-2357. (Pubitemid 46218728)
51. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988; 319:1676-1680. (Pubitemid 19015247)
52. Cote AL, Usherwood EJ, Turk MJ. Tumor-specific T-cell memory: Clearing the regulatory T-cell hurdle. Cancer Res 2008; 68:1614-1617. (Pubitemid 351416543)
53. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, et al. Synergism of cytotoxic T lymphocyteassociated antigen 4 blockade and depletion of CD25( +) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 2001; 194: 823-832. (Pubitemid 32983017)
54. 4+CD25+ regulatory T cells. J Immunol 2005; 174:90-98. (Pubitemid 40007395)
55. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999; 59:3128-3133. (Pubitemid 29316012)
56. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25 +CD4 + T cells: A common basis between tumor immunity and autoimmunity. J Immunol 1999; 163:5211-5218.
57. Stephens GL, McHugh RS, Whitters MJ, Young DA, Luxenberg D, Carreno BM, et al. Engagement of glucocorticoid-induced TNFR familyrelated receptor on effector T cells by its ligand mediates resistance to suppression by CD4 +CD25 + T cells. J Immunol 2004; 173:5008-5020. (Pubitemid 39387783)
58. Huang CT,Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity 2004; 21:503-513. (Pubitemid 39370506)
59. 4+ regulatory T cell function. Science 2005; 309:1380-1384. (Pubitemid 41209366)
60. Dominguez-Soto A, Sierra-Filardi E, Puig-Kroger A, Perez-Maceda B, Gomez-Aguado F, Corcuera MT, et al. Dendritic cell-specific ICAM-3- grabbing nonintegrin expression on M2-polarized and tumor-associated macrophages is macrophage-CSF dependent and enhanced by tumorderived IL-6 and IL-10. J Immunol 2011; 186:2192-2200.
61. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 2006; 203:871-881.
62. Quandt D, Fiedler E, Boettcher D, MarschW, Seliger B. B7-h4 expression in human melanoma: Its association with patients' survival and antitumor immune response. Clin Cancer Res 2011; 17:3100-3111.
63. Pedicord VA, Montalvo W, Leiner IM, Allison JP. Single dose of anti-CTLA-4 enhances CD8 + T-cell memory formation, function, and maintenance. Proc Natl Acad Sci USA 2011; 108:266-271.
64. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23:6043-6053.
65. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009; 15:5591-5598.
66. Robert C, Thomas L, Bondarenko I, O'Day S, MD J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 26:2517-2526.
67. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002; 8:793-800.
68. YangW, Chen PW, Li H, Alizadeh H, Niederkorn JY. PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro. Invest Ophthalmol. Vis. Sci. 2008; 49: 2518-2525.
69. Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, Pai SI, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 2001; 193:839-846.
70. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002; 99:12293-12297.
71. Hirano F, Kaneko K, Tamura H, Dong H,Wang S, Ichikawa M, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005; 65:1089-1096. (Pubitemid 40216472)
72. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010; 116:1757-1766.
73. Curran MA, MontalvoW, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010; 107:4275-4280.
74. Ito M, Minamiya Y, Kawai H, Saito S, Saito H, Nakagawa T, et al. Tumor-derived TGFbeta-1 induces dendritic cell apoptosis in the sentinel lymph node. J Immunol 2006; 176:5637-5643.
75. Porter GA, Abdalla J, Lu M, Smith S, Montgomery D, Grimm E, et al. Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes. Ann Surg Oncol 2001; 8: 116-122. (Pubitemid 32199407)
76. Botella-Estrada R, Dasi F, Ramos D, Nagore E, Herrero MJ, Gimenez J, et al. Cytokine expression and dendritic cell density in melanoma sentinel nodes. Melanoma Res 2005; 15:99-106. (Pubitemid 40637987)
77. Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH. Interleukin-10- treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8( +) T cells resulting in a failure to lyse tumor cells. Blood 1999; 93:1634-1642. (Pubitemid 29102491)
78. Botella-Estrada R, Escudero M, O'Connor JE, Nagore E, Fenollosa B, Sanmartin O, et al. Cytokine production by peripheral lymphocytes in melanoma. Eur Cytokine Netw 2005; 16:47-55. (Pubitemid 40478076)
79. Lee JH, Torisu-Itakara H, Cochran AJ, Kadison A, Huynh Y, Morton DL, Essner R. Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res 2005; 11:107-112. (Pubitemid 40075784)
80. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004; 114:280-290. (Pubitemid 39071633)
81. Wu L, Zhang W, Liu H. Immunohistochemical study of angiogenesis of axillary lymph node metastasis in human breast carcinoma. Zhonghua Zhong Liu Za Zhi 1999; 21:433-435.
82. Skobe M, Hamberg LM, Hawighorst T, Schirner M, Wolf GL, Alitalo K, Detmar M. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol 2001; 159:893-903. (Pubitemid 32847180)
83. Kukk E, Lymboussaki A, Taira S, Kaipainen A, Jeltsch M, Joukov V, Alitalo K. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 1996; 122:3829-3837. (Pubitemid 27033879)
84. Boone B, Blokx W, De Bacquer D, Lambert J, Ruiter D, Brochez L. The role of VEGF-C staining in predicting regional metastasis in melanoma. Virchows Arch 2008; 453:257-265.
85. Schietroma C, Cianfarani F, Lacal PM, Odorisio T, Orecchia A, Kanitakis J, et al. Vascular endothelial growth factor-C expression correlates with lymph node localization of human melanoma metastases. Cancer 2003; 98: 789-797. (Pubitemid 36959276)
86. Massi D, Puig S, Franchi A, Malvehy J, Vidal-Sicart S, Gonzalez-Cao M, et al. Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: A case-control study. J Clin Pathol 2006; 59:166-173. (Pubitemid 43235582)
87. Harrell MI, Iritani BM, Ruddell A. Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. Am J Pathol 2007; 170:774-786. (Pubitemid 47339411)
88. Hirakawa S, Brown LF, Kodama S, Paavonen K, Alitalo K, Detmar M. VEGFC- induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 2007; 109:1010-1017. (Pubitemid 46220646)
89. Goydos JS, Gorski DH. Vascular endothelial growth factor C mRNA expression correlates with stage of progression in patients with melanoma. Clin Cancer Res 2003; 9:5962-5967. (Pubitemid 38018082)
90. Emmett MS, Lanati S, Dunn DB, Stone OA, Bates DO. CCR7 mediates directed growth of melanomas towards lymphatics. Microcirculation 2011; 18:172-182.
91. Simonetti O, Goteri G, Lucarini G, Filosa A, Pieramici T, Rubini C, et al. Potential role of CCL27 and CCR10 expression in melanoma progression and immune escape. Eur J Cancer 2006; 42:1181-1187.
92. Essner R, Kojima M. Dendritic cell function in sentinel nodes. Oncology (Williston Park, NY) 2002; 16:27-31.
93. Cochran AJ, Morton DL, Stern S, Lana AM, Essner R, Wen DR. Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: Implications for tumor biology and treatment. Mod Pathol 2001; 14:604-608. (Pubitemid 32554086)
94. Polak ME, Johnson P, Di Palma S, Higgins B, Hurren J, Borthwick NJ, et al. Presence and maturity of dendritic cells in melanoma lymph node metastases. J Pathol 2005; 207:83-90. (Pubitemid 41200717)
95. Enk AH, Jonuleit H, Saloga J, Knop J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 1997; 73:309-316. (Pubitemid 27508890)
96. Van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)- producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 1999; 190:355-366. (Pubitemid 29374833)
97. Longo-Imedio MI, Longo N, Trevino I, Lazaro P, Sanchez-Mateos P. Clinical significance of CXCR3 and CXCR4 expression in primary melanoma. Int J Cancer 2005; 117:861-865. (Pubitemid 41598840)
98. Perez DG, Suman VJ, Fitch TR, Amatruda T 3rd, Morton RF, Jilani SZ, et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: A North Central Cancer Treatment Group study, N047A. Cancer 2009; 115:119-127.
99. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70:6171-6180.